Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer

NCT ID: NCT02739529

Last Updated: 2017-05-01

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-30
• Study Completion Date: 2018-03-31

Brief Summary

Dose-dense paclitaxel (Genexol®-PM) once a week in combination with carboplatin every 3 weeks for gynecologic cancer (adult solid tumor): a phase I trial.

Conditions

Gynecologic Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1

Group Type: EXPERIMENTAL

Genexol-PM

Intervention Type: DRUG

Cremophor EL-free polymeric micelle of paclitaxel

Cohort 2

Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1

Group Type: EXPERIMENTAL

Genexol-PM

Intervention Type: DRUG

Cremophor EL-free polymeric micelle of paclitaxel

Cohort 3

Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1

Group Type: EXPERIMENTAL

Genexol-PM

Intervention Type: DRUG

Cremophor EL-free polymeric micelle of paclitaxel

Interventions

Genexol-PM

Cremophor EL-free polymeric micelle of paclitaxel

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients who aged 20 years or older and under 80 year old female

2. Patients who were diagnosed histologically or cytologically or who were scheduled to reccur as an gynecologic cancer (epithelial ovarian cancer , fallopian tube cancer, primary peritoneal cancer, cervical cancer, uterine corpus cance, etc)

3. Patients seemed appropriate for Paclitaxel and Carboplatin combination therapy for the treatment

4. Patients whose ECOG performance score are 0-2

5. Patients who have adequate blood, kidney and liver function on screening within 14 days before the administration of the test drugs

• Hb ≥ 10g/dl: Patients with less than 10g/dl of hemoglobin level were not allowed to use the test drugs unless they were recovered to 10g/dl or more.
• ANC ≥ 1500/mm3
• Platelet Count ≥ 100,000/mm3
• Serum AST and ALT ≤ 2.5 X ULN
• Serum ALP ≤ 2.5 X ULN
• Serum creatinine ≤ 2.5 X ULN

6. Patients who participated voluntarily and who provided written informed consent before participating in the study

Exclusion Criteria

1. Patients with the history of carcinoma in the past 5 years other than gynecologic cancer

2. Patients who received radiotherapy at abdominal cavity or pelvis

3. Patients who were receiving immunotherapy or hormone therapy

4. Patients who received a major surgery other than debulking surgery within 2 weeks before the screening

5. Patients with a past or present medical history of metastasis in central nervous system (CNS)

6. Patients with NCI CTCAE V4.0 Grade 1 or more sensory or motor neuropathy

7. Patients with severe comorbidities as follows

• medical or mental condition impossible to understand the clinical trial and provide a written informed consent, based on the investigators' decision
• severe cardiovascular disease (such as ischemic heart disease requiring medical therapy, myocardial infarction within the last 6 months, and grade 2~4 congestive heart failure defined by New York Heart Association criteria)
• uncontrolled active infectious disease
• hypersensitivity to the test drugs or the vehicle

8. Patients who participated in another study within 4 weeks before the screening

9. Pregnant, lactating women or Patients who do not use contraceptive methods that can be medically accepted to the possibility of pregnancy in female volunteers

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Samyang Biopharmaceuticals Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yong Man Kim

Role: PRINCIPAL_INVESTIGATOR

Asan Medical Center

Locations

Samyang Biopharmaceuticals

Seoul, , South Korea

Site Status: RECRUITING

Countries

South Korea

Facility Contacts

Miryung Jin

Role: primary

miryung.jin@samyang.com

+82-2-740-7289

Other Identifiers

GPMOC101

Identifier Type: -

Identifier Source: org_study_id